Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02311907CT.gov Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral Neuropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Glutathione (this asset) | Alliance for Clinical Trials in Oncology | P3 | BB · 64 |
| Pregabalin | University of Rochester | P4 | A |
| Lidocaine | University of Utah | P4 | BBB |
| Nabiximols | VA Office of Research and Development | P3 | BBB |
| Gabapentin | Washington University School of Medicine | P4 | BB |
| Oxaliplatin | Tanta University | P3 | BB |
| Ziconotide | Aaron Boster | P4 | BB |
| yhd1119 | Yuhan Corporation | P3 | BB |
| Capsaicin | Astellas Pharma Europe Ltd. | P4 | BB |
+42 more in the Peripheral Neuropathy cohort
Other indications for Glutathione
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Toxic Encephalopathy | — | P3 | BB · 64 |
| Fallopian Tube Cancer | — | P3 | BB · 64 |
| Ovarian Cancer | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Glutathione in Peripheral Neuropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/glutathione-peripheral-neuropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →